Barclays
NAMS icon

Barclays’s NewAmsterdam Pharma NAMS Stock Holding History

Barclays’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$697K Buy
21,780
+16,128
+285% +$525K ﹤0.01% 2978
2025
Q4 		$198K Sell
5,652
-66
-1% -$2.4K ﹤0.01% 4325
2025
Q3 		$163K Sell
5,718
-12,153
-68% -$291K ﹤0.01% 4419
2025
Q2 		$324K Buy
17,871
+1,986
+13% +$36.2K ﹤0.01% 4010
2025
Q1 		$325K Sell
15,885
-828
-5% -$18.4K ﹤0.01% 3782
2024
Q4 		$430K Buy
16,713
+9,117
+120% +$194K ﹤0.01% 3922
2024
Q3 		$126K Buy
7,596
+7,199
+1,813% +$125K ﹤0.01% 4508
2024
Q2 		$7.63K Buy
397
+303
+322% +$6.08K ﹤0.01% 4543
2024
Q1 		$2.22K Sell
94
-419
-82% -$8.5K ﹤0.01% 4911
2023
Q4 		$5.73K Hold
513
– – ﹤0.01% 5021
2023
Q3 		$4.75K Buy
+513
New +$5.55K ﹤0.01% 4391

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Barclays's NAMS Position: Q1 2026 in Review

Barclays increased its NewAmsterdam Pharma (NAMS) stake by 285% in Q1 2026, buying an estimated $525K and bringing the position to 21,780 shares worth $697K. The position accounts for ﹤0.01% of the portfolio, ranked #2978.

Barclays first reported a position in NAMS in Q3 2023 and has held it in 11 quarters since. 171 funds tracked by Wall St. Rank hold NAMS as of Q1 2026.

  • Barclays held 21,780 shares of NewAmsterdam Pharma worth $697K as of Q1 2026.
  • Barclays bought 16,128 NewAmsterdam Pharma shares in Q1 2026, an estimated $525K.
  • NewAmsterdam Pharma made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2978 holding.
  • Barclays first reported a position in NewAmsterdam Pharma in Q3 2023 and has held it in 11 quarters since.
  • 171 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.